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Intrahepatic lymphocytesLiver disease is an increasing global health burden. Theﬁnal sequalae of cirrhosis, liver failure and hepatocellular carcino-
ma are often the result of inﬂammation driven by intrahepatic lymphocytes. Accurate assessment of organ-speciﬁc dis-
eases ideally employs tissue sampling though this is rarely performed. Here we report our experiences of utilising
repeated ﬁne needle aspirations (FNAs) to assess liver-derived leukocytes. In 88 patient samples, we obtained a mean
of 36,959 lymphocytes from each FNA-derived biopsy (SD 22,319 cells, range 5034–91,242 cells) measured by ﬂow cy-
tometry. This quick technique requiredminimal analgesia compared to liver biopsy (p= 0.03); was well tolerated and
safe, and hence repeated sampling up to 3 timeswithin aweekwas feasible.We detail the technique to rapidly derive a
single cell suspension suitable formultiparameterﬂow cytometry analysis. Finallywe illustrate the importance of organ-
derived sampling by showing that natural killer (NK) cells from FNA samples have amarkedly altered phenotype com-
pared to those assessed in peripheral blood. In combination these data validate FNA as a powerful and well-tolerated
method of sampling intrahepatic lymphocytes to study the immunology of acute and chronic liver diseases.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/cc-by/4.0/).1. Introduction
Inﬂammatory liver diseases, including chronic viral hepatitis, autoim-
mune hepatitis and steatohepatitis, represent a major global health bur-
den. Lymphocytes are often stated to be the drivers of these clinical
disorders, but direct evidence is often lacking. It iswell recognised that, al-
though easy to sample, peripheral blood lymphocytesmay not reﬂect the
function and phenotype of cells within the liver. Sampling cells from
within the liver has remained problematic. Liver biopsy, using 16–18
gauge sheathed (Tru Cut) needles or suction (Menghini) needles,
remains the clinical gold standard to assess liver ﬁbrosis and inﬂamma-
tion and can provide valuable diagnostic information. However, the
invasive nature of the liver biopsy, coupled with signiﬁcant morbidity
(and very rarely mortality) has driven interest in development of
biochemical and non-invasive markers (i.e. liver elastography) to assess
chronic liver disease (Castera, 2012). Percutaneous liver biopsyhas amor-
tality rate of 1 in 10,000 and themost common complication is abdominal
or right shoulder pain in up to 25% of patients (Bravo et al., 2001). Whilst
the parenchyma of the liver has a relatively paucity of nerve ﬁbres the
liver capsule is well innervated and together with the skin requires inﬁl-
tration with local anaesthetic; in spite of this some patients require addi-
tional analgesia. Other rare (b1%) risks associated with liver biopsyd Immunity, Henry Wellcome
h Park, Cardiff CF14 4XN, UK.
This is an open access article under thinclude bleeding, pneumothorax, perforation and peritonitis (Bravo
et al., 2001).
To gain a sufﬁcient number of lymphocytes for analysis, it has been
necessary to obtain a separate biopsy core designated for research
purposes. The risk of complications from liver biopsy obviously in-
creases with the number of passes of the needle into the liver. This sep-
arate core requires physical and enzymatic degradation to isolate
lymphocytes. The clinical risks associated with liver biopsy prevent
the use of this technique to monitor lymphocytes at frequent intervals
within the same individual (Ahlenstiel et al., 2011). During interferon-
based treatment of viral hepatitis, we and others have found that the
largest reductions in viral load take place during the ﬁrst week, thus it
would be useful to closely monitor intrahepatic changes during this pe-
riod of marked perturbation (Davis et al., 2003; Pembroke et al., 2012).
These limitations to the use of standard liver biopsy techniques led
us to explore the use of Fine Needle Aspiration (FNA) to obtain samples.
FNA needles rely on aspiration of a clinical sample via a small-bore
needle (usually 23 gauge). This is a clinical technique that provides
single cell cytology samples and as such is unable to provide histological
information. However, it is reliable, relatively safe and often provides
the required diagnostic information. FNA has been used to obtain
lymphocytes from organs to monitor disease (Oliveira et al., 1997;
Claassen et al., 2011).
Aspiration of tissue fromwithin a solid organ, including fromwithin
the liver capsule, will inevitably contain a mixture of blood cells and
cellular debris from the stroma. A hurdle to the use of FNA as a
technique to sample intrahepatic lymphocytes is the need to removee CC BY license (http://creativecommons.org/licenses/cc-by/4.0/).
132 T. Pembroke et al. / Journal of Immunological Methods 424 (2015) 131–135sampling debris to enable effective labelling of lymphocytes and
analysis by ﬂow cytometry. In this report we discuss our experiences
of performing88 liver FNAs to sample intrahepatic lymphocytes, includ-
ing repeat FNA sampling on a subset of 9 patients. We discuss the
practicality of this approach with respect to patients' tolerance, the
procedure itself and sample processing. We also highlight comparative
datasets obtained from intrahepatic and blood lymphocytes derived
from the same individuals.
2. Methods
2.1. Ethics statement
South East Wales Local Research Ethics Committee reviewed this
project (10/WSE02/45). Patients who participated were given a study
information sheet and provided informed written consent.
2.2. Study subjects
Fifty-three consecutive patients attending the hepatology department
for outpatient liver biopsy or IFNα treatment of HCVwere recruited. Liver
biopsy was performed on 49 individuals as part of their routine workup
whereas FNA alone was conducted on 4. Nine patients undergoing IFNα
treatment were sampled by FNA a combined total of 35 times at days 1,
3, 7, and 14 & months 1, 3 and 6 following the initiation of treatment
(Table 1).
FNA samples were taken in a day case treatment room in the
University Hospital of Wales. Prior to the FNA, all patients
underwent a recent ultrasound scan and α-fetoprotein (to exclude
abnormal anatomy and intrahepatic lesions) and routine clinical
bloods (full blood count, liver biochemistry, coagulation screen)
were assessed. Patients were considered eligible for the procedure
if platelets were N60, 000/μl and prothrombin time b14.5 s in
keeping with local liver biopsy guidelines. Patients were seen on an
outpatient basis with a view to discharge following the procedure.
Clinicians experienced in biopsying the liver undertook this
procedure. Written informed consent was obtained—the risks we
described relating to the FNA procedure are as follows:
• Common: approximately 10–25% of procedures:
B Bruising and soreness
• Serious complications: b than 1 in every 10,000 procedures:
B Bleeding requiring blood transfusion
B Damage to organs surrounding the liver—including the lung, bowel
and gallbladder
B Peritonitis
B PneumothoraxTable 1
FNA donor characteristics.
Characteristics Chronic liver disease HCV
Number 29 24
Mean age (range) 50.6
(29–69)
49
(27–65)
Male:female 16:13 17:7
Median viral load (range) – 1.3 × 106
(1.9 × 103–3 × 107)
Median NI score (range) 1
(0–6)
5
(2–8)
Median ﬁbrosis score (range) 2
(0–6)
2
(0–2)
HCV genotype
1
3
–
–
16
8Separate written consent for liver biopsy was obtained in the usual
manner for those undergoing both procedures.
2.3. Materials for Fine Needle Aspiration
1. Roswell Park Memorial Institute (RPMI, Gibco, Paisley UK) media
supplemented with 10% foetal calf serum, 250 μl heparin, 100 U/ml
penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 2 mM
sodium pyruvate (R-10), stored on ice.
2. Sterile dressing pack (Rocialle, Mountain Ash UK) including gloves,
gauze swabs, gallipot and sterile paper ﬁeld.
3. 1% tincture of iodine solution (Videne).
4. 5 and 10 ml syringes.
5. Orange (25 gauge), Green (21 gauge) and White (19 gauge)
hypodermic needles (BD Oxford UK).
6. 10 ml 2% lignocaine (Braun, Melsugen Germany).
7. 22 gauge spinal needle Quinke type pointwith an internal trocar (BD,
Oxford UK).
8. Sterile dressing for puncture site (Premier, Enﬁeld UK).
2.4. Fine Needle Aspiration technique
We have developed the following protocol for FNA sampling of
intrahepatic lymphocytes. Standard aseptic clinical procedure is
observed using a plastic disposable apron, sterile gloves and sterile
disposable towels.
1. Obtain a heparinised blood sample for density gradient isolation of
lymphocytes as previously described (Gallagher et al., 2009).
2. Place the patient in the supine position with the right hand behind
the head. Percuss the lower edge of the liver in the right mid-
axillary line and mark suitable site 1–2 intercostal spaces above
the lower edge; this is usually 2 intercostal spaces above the costal
margin. Conﬁrm that the marked position for FNA sampling over
the liver is dull on percussion in full expiration.
3. Clean the skin with iodine solution.
4. Draw up 5 ml 2% lignocaine into a 5 ml syringe; inject 1–2 ml into
the dermis with a 25-gauge orange needle. Allow the lignocaine
to take effect (30–60 s), then replace this needle with a 23-gauge
green needle and continue to inﬁltrate 2% lignocaine through the
intercostal muscles to the hepatic capsule. Occasionally a longer
21 gauge white needle is required for larger patients.Fig. 1. Post procedure analgesia. Analgesia was offered to patients at regular intervals fol-
lowing FNA and liver biopsy procedures. 2 patients requested simple analgesia after FNA
alone; 16 patients who underwent FNA followed by biopsy requested simple analgesia
and 2 required pethidine p = 0.0004 χ2 test. Of 22 patients who had biopsy alone 6 re-
quired cocodamol and 2 required pethidine (v FNA alone p = 0.025 χ2 test); there was
no signiﬁcant difference in analgesia requirement in biopsy alone v biopsy and FNA
(p = ns χ2 test).
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the anaesthetised tract to the edge of liver capsule. Instruct the pa-
tient to inhale, then exhale fully and hold their breath in full
expiration. The needle can then be inserted 2–3 cm into the liver pa-
renchyma from the capsule.
6. Remove the internal trocar and attach a 10 ml syringe ﬁlled with
ice-cold R-10 and aspirate using gentle negative syringe pressure
as the needle is withdrawn 1–2 cm but remaining within the liver
parenchyma.
7. Remove the needle and draw freshmedia into the syringe to ensure
that the entire aspirate passes into the syringe.
8. Detach the syringe and replace the trocar and insert the needle
through the same anaesthetised tissue but orientated in a slightly
different direction when passing into the liver. Repeat the aspira-
tion as in (6) and (7).Fig. 2. Lymphocyte gating strategy. Intrahepatic lymphocytes were stained with ﬂuorochrome l
tiﬁed by forward scatter height and area. B) Lymphocytes were gate based on forward and side
cells and CD3+ T lymphocytes. E & F) intrahepatic NK cells had markedly reduced CD16 expre9. The contents of the syringe are promptly passed into a 50ml Falcon
tube on ice containing a further 20ml R-10 and then transported to
the lab for immediate staining as described in below.
10. Apply a simple plaster over aspiration site. Dress thewound site. The
patient can be discharged in b30 min if there are no adverse effects.
Patients can resume normal daily activities. We advised the patient
to keep the wound site clean and dry, and avoid heavy lifting, for 24 h.2.5. Preparation of samples for ﬂow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated using a
Ficoll density gradient. Various techniques were employed to separate
intrahepatic lymphocytes from debris associated with the FNA sampling.abelledmonoclonal antibodies and analysed by ﬂow cytometry. A) Single cells were iden-
scatter. C) Aqua staining to exclude dead cells. D) CD56+ CD3−NK cells, CD56+ CD3+NKT
ssion compared to the peripheral blood.
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Initially samples were passed through a 70 μm cell strainer (Fischer
Scientiﬁc, Loughborough UK) and centrifuged at 1600 RPM for 5 min.
The pellet was resuspended in 5 ml of R-10 and layered over Ficoll
and centrifuged for 2000 RPM for 20 min. Although an interface was
not evident the solution above the Ficoll layer was harvested and
stained as described below.
2.5.2. Method 2
Samples were centrifuged at 1600 RPM for 5 min and resuspended
in cold phosphate buffered saline (PBS). This step was repeated and
cells were subsequently plated for ﬂuorochrome labelled monoclonalFig. 3. Intrahepatic lymphocyte isolation by permeabilisation and density gradient tech-
niques. Lymphocytes isolated from FNA aspirates were prepared by cell permeabilisation
andwashing, which broke up cell debris and by Ficoll density gradient. A) Total number of
lymphocytes retrieved. B) The proportion of NK cells of total lymphocytes retrieved. C) NK
cell CD16 expression using both techniques. Mean and SEM shown.antibody staining. Cell surface markers were stained. Debris was
removed during 0.5% saponin permeabilisation (ebioscience, Hatﬁeld
UK) and samples were washed 3 times in permeabilisation buffer
(ebioscience, Hatﬁeld UK). Intracellular cytokines were then stained
using labelled antibodies.
2.6. Immunophenotyping and intracellular staining
Both intrahepatic lymphocytes and PBMCwerewashed twice in PBS
and stainedwithAqua live/dead stain (Invitrogen, Paisley, UK) andﬂuo-
rochrome labelled monoclonal antibodies speciﬁc for CD3-APCH7, (BD
Biosciences, Oxford) CD16-FITC, (eBioscience, Hatﬁeld, UK) and CD56-
PerCP.Cy5 (Biolegend, Cambridge, UK). Cells were then permeabilised
and ﬁxed with Fix/Perm solution (eBioscience, Hatﬁeld, UK) according
to the manufacturer's instructions, washed and stained with antibodies
speciﬁc for granzyme B-APC (Invitrogen, Paisley UK) and IFNγ-e450
(eBioscience, Hatﬁeld, UK). Cells were washed and ﬁxed with 2%
paraformaldehyde solution and analysed by ﬂow cytometry as
described above.
2.7. Statistical analysis
Comparisons of lymphocyte numbers and phenotypic markers were
made using either the Student t-test (assuming normal distribution of
data) or the Mann–Whitney U test (for data without normal distribu-
tion). χ2 test was used to compare analgesia requirements between
the FNA and biopsy groups. The software employed was Excel 2011
and GraphPad Prism 5.0.
3. Results and discussion
3.1. Results
3.1.1. Patient outcome and side effects
The FNA sampling technique described here was applied to a cohort
of 53 patients. Nine patients had FNA samples taken at multiple time
points (Table 1) resulting in a total of 81 intrahepatic samples obtained
for lymphocyte analysis. The procedure is well tolerated. Following the
39 FNAs alone (i.e. did not proceed to Tru-Cut liver biopsy) 1 patient
required 1 g of paracetamol and 1 patient received 30 mg of codeine
and 500 mg of paracetamol. When patients proceeded to liver biopsies
following FNA there was a marked increase in the need for analgesia
compared to FNA alone, with 16 patients requiring cocodamol and 2
patients required intramuscular pethidine (χ2 p = 0.0004, Fig. 1).
Twenty-two consecutive patientswhohad biopsy alonewere reviewed.
The analgesia requirements of individuals who had FNA and biopsy
were not increased compared to those who had biopsy alone. Individ-
ualswhohad FNAalonehad a signiﬁcantly lower analgesia requirement
than those who had biopsy alone (χ2 p = 0.03 Fig. 1). Of note a signiﬁ-
cant proportion of patients (9/12) who commenced treatment with
IFNα agreed to repeated FNA sampling with up to three samples
taken during the ﬁrst week. There were no other complications
associated with the FNA sampling or liver biopsies in this cohort.
3.1.2. Phenotype of lymphocytes puriﬁed after FNA
Two methods to isolate intrahepatic lymphocytes from the aspirate
were tested. As described inMaterials andmethods, theﬁrstmethod re-
quired layering aspirate upon Ficoll and isolating lymphocytes using a
density gradient. The second method utilised saponin permeabilisation
and repeated washing to clear cell debris. In both methods, cells were
stained with monoclonal antibodies and phenotype and function were
assessed using ﬂow cytometry as follows: Single cells were selected
using forward scatter height and forward scatter area gating. Lympho-
cytes were then gated based on forward and side scatter and dead
cells were excluded with aqua live dead stain. Lymphocyte subsets
(NK, NKT and T lymphocytes) were gated based upon expression of
135T. Pembroke et al. / Journal of Immunological Methods 424 (2015) 131–135CD56 and CD3 (Fig. 2A–E). Compared to NK cells in matched PBMC
samples, the phenotype of intrahepatic NK cells retrieved by FNA was
markedly altered. Whilst the proportion of CD56Dim NK cells was
unaltered, the proportion of CD16+ NK cells was signiﬁcantly lower
(p b 0.0001, Fig. 2F) indicating that distinct NK cell populations were
obtained (Pembroke et al., 2014).
The number of lymphocytes retrieved by the saponin
permeabilisation and density gradient methods were compared.
The number of intrahepatic lymphocytes retrieved was signiﬁcantly
higher using permeabilisation compared to a density gradient (mean
lymphocytes = 36,959 v 2183 respectively p b 0.0001, Fig. 3A). The
proportion of NK cells was similar using both methods (10.8% v
12.1% p = 0.7, Fig. 3B). Whilst it is difﬁcult to accurately assess the
phenotype of such small numbers of cells retrieved using density
gradient separation, proportions of CD16+ NK cells were similar
with both methods (72.5% v 67.0% p = 0.46, Fig. 3C).3.2. Discussion
In this report we describe in detail a FNA technique to sample
intrahepatic lymphocytes. It is important to note that these FNA
samples are taken from the intracapsular space. As the liver is an
extremely vascular organ it is likely that the needle may have passed
through small sinusoids. If samples were heavily blood stained then
theywere discarded and the needle passed into fresh liver, this occurred
on less than 5 passes of the spinal needles during the study period. The
marked alteration inNKcell phenotype conﬁrms thatwewere sampling
a truly separate population to the peripheral blood, as we have
described previously (Pembroke et al., 2014).
These protocols can be utilised to sample and study lymphocytes
from the intrahepatic compartment providing novel insights into
inﬂammatory liver diseases. The number of lymphocytes retrieved
allows a phenotypic and functional analysis by ﬂow cytometry. Other
potential applications include gene expression analysis, protein arrays,
and functional T-cell assay e.g. ELISpots. This procedure is well tolerated
and acceptable to patients allowing collection of multiple samples dur-
ing a week, thereby providing a unique insight into the kinetics of
intrahepatic responses (Pembroke et al., 2014).4. Conclusion
In conclusion, the protocol presented in this paper describes a simple
approach for isolation of intrahepatic lymphocytes. These cells can be
easily prepared for analysis by ﬂow cytometry or other techniques.
The application of this technique can provide samples for a broad
range of immunological assays. We anticipate that this protocol will
be helpful in studies of a range of inﬂammatory liver disorders.
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